Literature DB >> 8322545

[The effectiveness of immunization with vaccinia virus type "MVA" against an infection with cowpox virus type "OPV 85" in rabbits].

E Munz1, S Linckh, I C Renner-Müller, M Reimann.   

Abstract

The immunological efficacy of vacciniavirus "MVA" was tested against a dermal and intradermal infection with cowpoxvirus "OPV 85" in rabbits: A single vaccination with "MVA" provided only insufficient immunity, a revaccination induced good immunity. Intramuscular immunizations protected better than subcutaneous applications. Immunized rabbits showed "revaccination reactions" after infection with "OPV 85" indicating a cellular immunity. After immunization with "MVA" and after infection with cowpoxvirus "OPV 85" all rabbits developed N- and ELISA-antibodies. HAI-antibodies were not found after immunization, but indicated a multiplication of cowpoxvirus after challenge. Vacciniavirus "MVA" is suggested for immunization of man and animal against possible infections with cowpoxvirus and cowpoxlike viruses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8322545

Source DB:  PubMed          Journal:  Zentralbl Veterinarmed B        ISSN: 0514-7166


  3 in total

1.  Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses.

Authors:  Zoe Waibler; Martina Anzaghe; Holger Ludwig; Shizuo Akira; Siegfried Weiss; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

2.  Field Trial Vaccination against Cowpox in Two Alpaca Herds.

Authors:  Almut Prkno; Donata Hoffmann; Matthias Kaiser; Daniela Goerigk; Martin Pfeffer; Karsten Winter; Thomas W Vahlenkamp; Martin Beer; Alexander Starke
Journal:  Viruses       Date:  2020-02-20       Impact factor: 5.048

3.  Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.

Authors:  Scott Parker; Ryan Crump; Scott Foster; Hollyce Hartzler; Ed Hembrador; E Randall Lanier; George Painter; Jill Schriewer; Lawrence C Trost; R Mark Buller
Journal:  Antiviral Res       Date:  2014-08-13       Impact factor: 10.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.